Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer–Related Lymphedema
The cytokine IFNα2A was identified as a potentially complementary biomarker to improve the stratification of high- and low-risk patients for BCRL. This will help enable earlier intervention to reduce long-term morbidity for those at high risk for lymphedema while minimizing burdensome interventions for those at low risk.
Authors
- Melissa B. Aldrich (ORCID: https://orcid.org/0000-0002-8114-7607)
- M. R. Hossack
- Cherie Xinyi. Lin
- Neil Lin (ORCID: https://orcid.org/0000-0002-3203-4497)
- Farnoosh Abbas‐Aghababazadeh (ORCID: https://orcid.org/0000-0001-6427-9379)
- Jie Su (ORCID: https://orcid.org/0000-0002-8402-9235)
- Simona F. Shaitelman (ORCID: https://orcid.org/0000-0002-7697-1263)
- Alison Wu
- Wei Xu
- Jennifer Y.Y. Kwan
- Wei Shi
- Fei-Fei Liu
Institutions
- Ontario Institute for Cancer Research (CA)
- University Health Network (CA)
- The University of Texas MD Anderson Cancer Center (US)
- University of Toronto (CA)
- Toronto Rehabilitation Institute (CA)
- Princess Margaret Cancer Centre (CA)
- Vector Institute (CA)
- Brown Foundation (US)
- Artificial Intelligence in Medicine (Canada) (CA)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2026-02-05
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0541
- Primary Topic
- Lymphatic System and Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- GlaxoSmithKline
- Cancer Care Ontario
- University of Toronto
- National Institutes of Health
- Canadian Institutes of Health Research
- National Cancer Institute